With increased globalization and migration of people, the likelihood of pandemics is projected to increase. Pandemics such as COVID-19 are associated with high rates of morbidity and mortality, and negatively impact the socioeconomic status and livelihoods of communities, particularly in resource-limited countries.
In these settings, the pharmaceutical sector has not been an exception, limiting access to quality and cost–effective medicines to control diseases in a region with already a high burden of infectious diseases and weak health systems
